APASL-ACLF without previous decompensation is immunologically distinct from EASL-CLIF-ACLF with previous decompensation
Open Access
- 6 October 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1893968
Abstract
Background and aims: Definitions of acute-on-chronic liver failure (ACLF) differ, with a focus on extrahepatic organ failures on the basis of previously compensated or decompensated cirrhosis in EASL-CLIF-ACLF versus hepatic failure in patients without previous decompensation in APASL-ACLF. Here, we explored whether patterns of systemic inflammation and immune cell alterations differ between these types of ACLF. Methods: Consecutive patients with acute decompensation, EASL-CLIF- or APASL-ACLF were recruited from two liver centres. Patterns of systemic inflammation were characterized by Olink analysis and changes in circulating immune cells by flow cytometry. Results: A total of 374 patients with acute decompensation (AD) were identified, of whom 56 fulfilled exclusively the EASL-CLIF-definition of ACLF (15% of all patients), while only 19 patients (5.1% of all patients) met exclusively the APASL-definition. APASL-ACLF was associated with higher bilirubin, lower creatinine, higher INR and higher hemoglobin concentrations compared to EASL-ACLF. Patterns of systemic inflammation differed between EASL-CLIF and APASL-ACLF. For example, FGF-23, IL-17 or VEGF-A were associated with EASL-CLIF-ACLF, while FGF-19 or low IL-12 were associated with APASL-ACLF. Moreover, patients with EASL-CLIF-ACLF had significantly lower counts of CD8+ T cells, while in APASL-ACLF a reduction of CD4+ T cell was characteristic. Detailed immune cell phenotyping revealed distinct expression of co-stimulatory molecules, inhibitory molecules and T cell activation markers in APASL-ACLF compared to patients with AD or EASL-CLIF-ACLF. Conclusion: We provide preliminary evidence that EASL-CLIF- and APASL-ACLF are associated with different changes in systemic inflammation patterns and immune cell phenotypes, suggesting that both types of ACLF might be pathophysiologically different.Keywords
This publication has 25 references indexed in Scilit:
- Development and validation of the A-TANGO organ failure score for acute-on-chronic liver failure in global cohortsJournal of Hepatology, 2026
- Investigating the expression of CD180, LY96, VCAM-1, and CSF2RB in the lipopolysaccharide response pathway across different liver cirrhosis etiologiesMolecular Biology Reports, 2025
- Impaired mitochondrial complex IV respiration in peripheral blood mononuclear cells discriminates acute-on-chronic liver failure from acute decompensationJournal of Hepatology, 2022
- Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failureJournal of Hepatology, 2022
- The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosisJournal of Hepatology, 2021
- The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiologyJournal of Hepatology, 2020
- Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLFJournal of Hepatology, 2020
- CD8+ T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunctionEBioMedicine, 2019
- Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an updateHepatology International, 2019
- Acute-on-chronic Liver FailureCurrent Gastroenterology Reports, 2016